Jansen Valerie Malyvanh 4

What Happened Valerie Malyvanh Jansen, a director of OnKure Therapeutics, was granted a derivative award covering 7,650 shares on June 4, 2026. The grant is reported with an acquisition price of $0.00 (total reported value $0). The filing identifies the award as a derivative (an option), not an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely).
• Transaction type: Grant / award of a derivative security (option) for 7,650 shares; reported acquisition price $0.00; reported value $0.
• Vesting: Per footnote, 100% of the shares subject to the option vest on the earlier of June 4, 2027 or the day prior to the issuer’s next annual meeting, subject to continued service.
• Shares owned after transaction: Not specified in the reported lines of this filing.
• No 10b5-1, tax withholding, or sale noted in this filing.

Context This is a time‑based option grant (derivative award) common as director compensation. It does not represent an immediate purchase or sale of stock and will only translate into actual shares if and when the option vests and is exercised under any applicable terms. Such grants are routine and reflect potential future ownership rather than current trading activity.